Literature DB >> 29239201

Cost effectiveness of preoperative screening for healthy patients undergoing robotic hysterectomy.

Michong K Rayborn1, John L Turner2, Sun G Park3.   

Abstract

The objective of this study was to determine whether routine preoperative type and screen blood testing is cost effective and medically warranted for benign diagnosis in healthy patients undergoing robotic hysterectomy. The study was designed as a cross sectional retrospective descriptive study. Four hundred and twenty two medical records of American Society of Anesthesiologists (ASA) Classifications I and II patients undergoing robotically-assisted laparoscopic hysterectomy between 1 June 2011 and 31 May 2014 at a 211 bed regional medical center were analysed. The results from this study paralleled the findings of other published research. Preoperative type and screen testing was performed on 249 (59%) of the patients in the study. Ten patients (2.4% of the group) converted to open laparotomy. Mean estimated blood loss was 59.59ml. No perioperative transfusions were required. The results indicate that preoperative type and screen testing is not warranted for patients meeting the inclusion criteria. Copyright the Association for Perioperative Practice.

Entities:  

Keywords:  Robotic assisted hysterectomy; Type and screen test; Value proposition

Mesh:

Year:  2017        PMID: 29239201     DOI: 10.1177/175045891702700603

Source DB:  PubMed          Journal:  J Perioper Pract        ISSN: 1750-4589


  2 in total

1.  Cost-Effectiveness of Routine Type and Screens in Select Endonasal Skull Base Surgeries.

Authors:  Aviv Spillinger; Meredith Allen; Patrick Karabon; Houmehr Hojjat; Kerolos Shenouda; Inaya Hajj Hussein; Jeffrey T Jacob; Peter F Svider; Adam J Folbe
Journal:  J Neurol Surg B Skull Base       Date:  2021-05-31

2.  Examining the Utility and Cost of Routine Type and Screen Prior to Minimally Invasive Hysterectomy.

Authors:  Anne Tjaden; Nicolette Codispoti; Linda C Yang; Thythy Pham
Journal:  JSLS       Date:  2021 Jul-Sep       Impact factor: 2.172

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.